The methods of diagnosing and treating localised prostate cancer has changed significantly in the last two decades.

Despite several randomized controlled trials demonstrating the benefits of combination therapies for metastatic hormone-sensitive prostate cancer (mHSPC), a significant treatment gap persists. This ...

GG1 prostate cancer can have heterogeneous outcomes, with some patients having intermediate- or high-risk disease, challenging the notion of GG1 as uniformly low-risk. Removing the cancer label for ...

There are different ways to manage fatigue during prostate cancer treatment, including exercise, sleep, complementary ...

In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPC; Real‑world evidence showed Pluvicto achieved longer PFS when init ...